The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 08, 2022

Filed:

Feb. 24, 2017
Applicant:

The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);

Inventors:

Joost J. Oppenheim, Rockville, MD (US);

De Yang, Frederick, MD (US);

Zhen Han, Frederick, MD (US);

Joseph John Barchi, Jr., Frederick, MD (US);

Michael Bustin, Rockville, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/69 (2017.01); A61K 9/51 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 31/664 (2006.01); C07D 215/00 (2006.01); A61K 45/06 (2006.01); A61K 38/17 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/4745 (2006.01); A61K 47/02 (2006.01); B82Y 5/00 (2011.01);
U.S. Cl.
CPC ...
A61K 47/6929 (2017.08); A61K 9/0019 (2013.01); A61K 9/51 (2013.01); A61K 9/5115 (2013.01); A61K 31/4745 (2013.01); A61K 31/664 (2013.01); A61K 38/1709 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/6923 (2017.08); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); B82Y 5/00 (2013.01);
Abstract

Methods of treating cancer or reducing the incidence of relapse of a cancer in a subject comprising co-administration of Toll-like receptor (TLR) 4 ligand, such as an HMGN1 protein, and a TLR 7 or 8 ligand, and optionally an immune checkpoint inhibitor, to the subject in need of such therapy. The TLR4-mediated immune-stimulating effect is synergistically enhanced by ligands of TLR7 or 8, and the immune checkpoint inhibitor. Also described here is a nanoparticle delivery platform for the co-administration of the TLR 4 ligand and the TLR 7 or 8 ligand.


Find Patent Forward Citations

Loading…